Nordson Corporation (NDSN) | The Buildout — AI Infrastructure
The Verdict
Nordson is a precision technology company whose dispensing, surface treatment, and inspection tools are used to assemble advanced semiconductor packages, including the high-bandwidth memory and chip-on-wafer-on-substrate stacks that power AI infrastructure. The company also serves medical and industrial markets, but its AI relevance comes from the Advanced Technology Solutions segment, where it helps customers place underfill, encapsulate dies, and verify chip-stack integrity. Nordson’s role is embedded in the manufacturing process — without its equipment, packaging lines would face requalification delays.
| Market Cap | — |
| Revenue (TTM) | $2.9B |
| Revenue Growth | +7.4% |
| EBITDA Margin (TTM) | 31.5% |
| Net Debt | $1.9B |
| Earnings Beats | 5 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- All three segments reached record Q2 sales, demonstrating organic growth of 7% — above the company’s 4–6% algorithm.
- Backlog expanded 18% organically year-on-year, providing multi-quarter revenue visibility and pushing some orders into FY2027.
- Over 50% of the portfolio is now in growth end markets, including semiconductor and medical, shifting the long-term growth profile.
- Free cash flow conversion hit 119% for the fourth consecutive quarter above 100%, enabling organic investment and de-levering.
- Management raised full-year guidance and articulated a clear framework: midpoint requires current trends, upper end needs electronics strength, low end only if macro deteriorates.
What We’re Watching
- Incremental margins at 31% remain 4–5 percentage points below target; persistent tariffs and inflation could cap near-term margin improvement.
- ATS organic growth decelerated to 8% from 21% on tough comps; re-acceleration in H2 is not assured.
- Medical interventional changeover temporarily compressed MFS margins; resolution timeline uncertain.
- Kulicke & Soffa’s panel-level dispense entry threatens Nordson’s leading position in advanced packaging — a direct competitive challenge.
The thesis is strengthening. Nordson is executing across all three segments, its backlog is building, and the semiconductor cycle appears early-stage. The portfolio shift toward higher-growth markets is bearing fruit. The open question is how sustainable the order surge proves to be and whether inflation dynamics let margins normalize.
Earnings Beat
Nordson posted Q2 fiscal 2026 revenue of $740.8 million, an 8% reported increase that included 7% organic growth. Gross margin held at 54.5% while EBITDA reached $233.5 million, a 31.5% margin. The standout was the backlog surge: organic backlog jumped 18% year-on-year, signaling orders well in excess of shipments.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $741M | $670M | $683M | +8.5% |
| Gross margin | 54.5% | 54.7% | 54.7% | -20bps |
| EBITDA | $234M | $203M | $206M | +13.2% |
| EPS | $2.09 | $2.38 | $1.97 | +6.0% |
| Organic backlog growth (YoY) | +18% | +4% | n/a | — |
Based on what you can see in the marketplace, based on what you can see with our customers, I would definitely tell you we’re in the early stages.— Sundaram Nagarajan, President and CEO, 2026-05-21
Management tone: Management’s tone shifted from cautious to markedly confident, driven by the backlog surge and medical recovery. They directly addressed tariff and inflation headwinds without spin, and offered a transparent guidance framework that gave investors clear contingencies.
Management Guidance
Full-year sales were raised to $2.93–$3.01 billion and adjusted EPS to $11.30–$11.80, with the CEO stating high confidence in the midpoint. Q3 was guided to sales of $760–$790 million and adjusted EPS of $2.95–$3.15. The guidance assumes foreign exchange turns neutral in the second half and that current demand trends, particularly in electronics, persist.
Trajectory
Nordson’s revenue has climbed from $682.9 million in the year-ago quarter to $740.8 million in Q2 FY2026, a 7% organic increase driven by all three segments. Gross margin was 54.5% while EBITDA margin expanded 130 basis points to 31.5%, helped by volume leverage in ATS. The order book grew far faster than sales: organic backlog surged 18% year-on-year, signaling robust demand that has yet to be converted into revenue. The company expects sequential growth to continue in Q3, guided to $760–$790 million.
The Model
The model projects FY+1 revenue of $3,010 million and EBITDA of $957 million (31.8% margin), followed by FY+2 revenue of $3,241 million and EBITDA of $1,044 million (32.2% margin). The near-term forecast is anchored by the current backlog and management’s raised guidance; FY+2 assumes sustained electronics demand and gradual margin recovery as incrementals normalize.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $2.8B | $3.0B | $3.2B |
| YoY Growth | — | +7.8% | +7.7% |
| EBITDA | $862M | $957M | $1.0B |
| EBITDA Margin | 30.9% | 31.8% | 32.2% |
Projections are the median of 5 independent model runs. The model’s revenue sits 3.2% above analyst consensus.
Full-year sales were raised to $2.93–$3.01 billion and adjusted EPS to $11.30–$11.80, with the CEO stating high confidence in the midpoint. Q3 was guided to sales of $760–$790 million and adjusted EPS of $2.95–$3.15. The guidance assumes foreign exchange turns neutral in the second half and that current demand trends, particularly in electronics, persist.
What Could Go Right — and Wrong
- ATS organic growth re-accelerates to double digits on easier comps in H2, confirming multi-year semiconductor cycle.
- Design wins for panel-level packaging or optical-fiber attach broaden Nordson’s content in advanced packaging.
- A bolt-on acquisition in medical or test & inspection uses the $900M balance-sheet capacity to add new growth.
- Incremental margins return to the mid-30s as tariffs and inflation moderate, lifting EBITDA above 33%.
- Broad-based organic growth sustains above 6%, proving the portfolio shift is lifting the long-term growth floor.
- AI-driven semiconductor demand plateaus earlier than expected, causing ATS orders to slow and backlog to normalize.
- Tariffs and raw-material inflation persistently keep incrementals at ~30%, permanently compressing margins.
- Kulicke & Soffa’s panel-level dispense captures key customers, eroding Nordson’s advanced packaging share.
- A sharp macro recession freezes industrial and medical orders, pushing revenue toward the low end of guidance.
- An overpriced M&A deal dilutes returns and weakens the balance sheet.
Looking Ahead
The next 12 months will be defined by whether Nordson’s semiconductor momentum proves durable and whether its industrial and medical segments can sustain their recent rebounds. The company enters the period with a record backlog and a clear path to at least the midpoint of its guidance, but the reality of tariffs and inflation will test its margin resilience.
- Q3 FY2026 (Aug 2026)Q3 earnings release — Tests whether the 18% backlog surge converts into $760-790M in revenue and whether ATS orders stay strong.
- H2 FY2026Incremental margin trajectory — If margin drop-through moves toward mid-30s, it confirms the company is offsetting tariffs/inflation.
- Late FY2026Medical headwind resolution — Regulatory-driven product changeover should complete, allowing MFS margins to recover.
- Q4 FY2026 (Dec 2026)Full-year report and FY2027 guide — Provides read on whether the semiconductor cycle is moderating or has further room to run.
- OngoingM&A announcement — With leverage at 1.9x and a new debt filing, a bolt-on acquisition could reshape the growth profile.
Financials
Annual Summary
| Metric | FY2025 | TTM |
|---|---|---|
| Revenue | $2.8B | $2.9B |
| Gross Margin | 55.1% | 55.1% |
| EBITDA | $862M | $1.7B |
| EBITDA Margin | 30.9% | 31.5% |
| Net Income | $484M | $528M |
| Free Cash Flow | $661M | $1.2B |
| Net Cash | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)55.1%
- EBITDA Margin (TTM)31.5%
- Net Margin (TTM)18.2%
- ROIC11.9%
- FCF Conversion78.5%
- SBC / Revenue0.3%
The Company
Nordson engineers and manufactures precision dispensing, surface treatment, and test & inspection systems used across semiconductor packaging, medical devices, and industrial manufacturing. Its tools apply underfill and encapsulation materials for advanced chip stacks, clean surfaces before bonding, and inspect for defects using X-ray and acoustic imaging. This equipment is critical for producing the high-bandwidth memory and chip-on-wafer-on-substrate packages that power AI infrastructure.
The company operates through three segments — Industrial Precision Solutions, Medical and Fluid Solutions, and Advanced Technology Solutions — and runs manufacturing facilities in ten countries. It relies on a high level of recurring revenue from aftermarket and consumables, which provides stability. The proprietary NBS Next framework drives operational improvements, including footprint repositioning closer to customers in Asia and lead-time reductions from 16–18 weeks to 4–8 weeks.
Business Segments
Competitive Landscape
Nordson’s primary competitive advantage is its full-stack capability — offering dispensing, surface treatment, and inspection tools together — giving it a strong position in advanced packaging lines. However, Kulicke & Soffa’s recent panel-level dispense product and Dover’s industrial dispensing presence challenge its share in specific sub-markets. The company’s high level of aftermarket and consumable revenue provides a recurring moat.
- Documented competitor in 10-K filings; competes in industrial dispensing and polymer processing.
- Kulicke & SoffaDirect competitor in semiconductor packaging; shipped a panel-level dispense solution in March 2026, a direct threat to NDSN’s advanced packaging ambitions.
- Graco (Asymtek brand)Inferred competitor in precision fluid dispensing for electronics, per supply-chain intelligence.
Supply Chain
Nordson sits between component suppliers and large semiconductor manufacturers and OSATs, providing the dispense and inspection tools essential for advanced chip packaging. No sole-source dependencies are disclosed, and no customer represents more than 10% of revenue.
More on NDSN: Earnings preview